DURHAM, N.C.--(BUSINESS WIRE)--KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced it entered into a subcontract with Mapp Biopharmaceutical, Inc. (Mapp) for the continued development and manufacturing of MBP134, an experimental combination monoclonal antibody treatment for Sudan ebolavirus (SUDV)*.
Contract development and manufacturing organization (CDMO) Avid Bioservices announced on Aug. 26, 2020 that Mapp Biopharmaceutical, a pharmaceutical company located in San Diego, CA, has selected Avid to provide process transfer, scale-up, and clinical manufacturing services for one of Mapp’s development programs for a novel antiviral drug candidate.